Swinging for the Fences: The Dichotomy in Rare Disease Investment and Development

9:00 AM - 10:15 AM, Thursday, June 6, 2019 ・ 106AB, Level 100
There's no denying that investments and drug development in rare and orphan diseases have increased tremendously over the last few years. It appears that venture capital is focusing on investments in this category because there seems to be a more capital efficient path to market along with dire patient need. This discussion will dive into the waves of change that have impacted the investments in this field, how investors balance the patient need with the need to get a return on investment and patient stories that have been instrumental in investments to date.
Spark Therapeutics, Inc.
General Partner
Sofinnova Ventures
Head of Business Development, Rare Diseases & Rare Blood Disorders, Global BD&L
Board Chair, Global Genes and Chief Patient Officer
Vitrisa Therapeutics